1237750-52-5Relevant articles and documents
A type-ii kinase inhibitor capable of inhibiting the T315I "Gatekeeper" mutant of Bcr-Abl
Choi, Hwan Geun,Ren, Pingda,Adrian, Francisco,Sun, Fangxian,Lee, Hyun Soo,Wang, Xia,Ding, Qiang,Zhang, Guobao,Xie, Yongping,Zhang, Jianming,Liu, Yi,Tuntland, Tove,Warmuth, Markus,Manley, Paul W.,Mestan, Jürgen,Gray, Nathanael S.,Sim, Taebo
experimental part, p. 5439 - 5448 (2010/11/05)
The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I "gatekeeper" mutation. Here we describe a type-II T315I inhibitor 2 (GNF-7), based upon a 3,4-dihydr